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PURPOSE. The purpose of this study was to develop a topical matrix metalloproteinase
inhibitor preparation for antiscarring therapy.
METHODS. The broad spectrum matrix metalloproteinase inhibitor ilomastat was formulated
using 2-hydroxypropyl-b-cyclodextrin in aqueous solution. In vitro activity of ilomastat-
cyclodextrin (ilomastat-CD) was examined using fibroblasts seeded in collagen. Permeation of
ilomastat-CD eye drop through pig eye conjunctiva was confirmed using Franz diffusion cells.
Ilomastat-CD eye drop was applied to rabbit eyes in vivo, and the distribution of ilomastat in
ocular tissues and fluids was determined by liquid chromatography-mass spectroscopy.
RESULTS. The aqueous solubility of ilomastat-CD was ~1000 lg/mL in water and 1400 lg/mL
in PBS (pH 7.4), which is greater than ilomastat alone (140 and 160 lg/mL in water and PBS,
respectively). The in vitro activity of ilomastat-CD to inhibit collagen contraction in the
presence of human Tenon fibroblast cells was unchanged compared to uncomplexed
ilomastat. Topically administered ilomastat-CD in vivo to rabbit eyes resulted in a therapeutic
concentration of ilomastat being present in the sclera and conjunctiva and within the aqueous
humor.
CONCLUSIONS. Ilomastat-CD has the potential to be formulated as an eye drop for use as an
antifibrotic, which may have implications for the prevention of scarring in many settings, for
example glaucoma filtration surgery.
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Matrix metalloproteinases (MMPs) are proteolytic enzymesthat are essential in wound healing, with roles in
inflammation and extracellular matrix remodeling.1 Diseases
related to uncontrolled extracellular matrix destruction with
upregulated MMP expression include inflammatory arthritis
and atherosclerosis.2,3 Broad spectrum inhibitors of MMP
(MMPi) have shown promise as modulators of healing with in
vitro studies showing the inhibition of fibroblast functions such
as migration, collagen production, and collagen contraction.4,5
Furthermore, these are nontoxic to ocular cells in vivo6,7 and in
vitro.4,5 Preclinical studies have shown that the synthetic broad
spectrum MMPi ilomastat can inhibit conjunctival scarring after
glaucoma filtration surgery in rabbits,6,7 in lens capsules
following simulated cataract surgery,8 and in models of
vitreoretinal contraction.9
The topical administration of ilomastat following glaucoma
surgery would potentially avoid the need for subconjunctival
injections. Ilomastat is poorly soluble in water (~140 lg/mL at
258C)10 and 161 lg/mL in balanced salt solution at 35.58C.11
Attempts to prepare sodium salts of ilomastat failed because
ilomastat is a weak hydroxamic acid with a relatively high pKa
¼ 8.912 that precluded salt formation at physiological pH
(unpublished data). Solubilization of ilomastat upon addition of
sodium hydroxide (ilomastat/NaOH, 1:2 molar ratio) was
observed, but the lyophilized powder of this solution was not
soluble in water (formation of suspension) (unpublished data).
Ilomastat has been reported to reduce corneal damage
caused by alkali burn in rabbits.13 Ilomastat was dissolved in
HEPES buffer containing 0.1% dimethylsulfoxide (DMSO) and
then administered topically to treat corneal damage in the
rabbits.13 The same vehicle was used to solubilize ilomastat in a
phase 1 clinical trial in healthy volunteers.14 Both safety and
efficacy of ilomastat were shown in phase I/II trials in patients
with bacterial keratitis induced corneal damage using topical
ilomastat, but development was discontinued because the
company (GlycoMed) merged with another company with
different interests.14,15 Increasing the amount of ilomastat
within an eye drop formulation would potentially result in an
adjunct therapy to treat fibrosis on the ocular surface and
within the subconjunctival space after glaucoma surgery.
Cyclodextrins (CDs) are hydrophilic cyclic oligosaccharides
that are able to form water soluble complexes with some
lipophilic drugs.16 CDs have been used preclinically to
formulate eye drops with drugs such as dorzolamide,17
cilostazol,18 natamycin,19 hydrocortisone,20 cyclosporine A,21
antihypertensive drugs,22 ciprofloxacin,22 tropicamide,23 pros-
taglandins,24 pilocarpine hydrochloride,25 and thalidomide.26
Several CD-based eye drops have been evaluated clinically, for
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example, latanoprost and dexamethasone,27–30 and several CD
eye drop formulations have been registered for clinical use, for
example, chromaphenicol (Clorocil, registered in Europe),
diclofenac (Voltaren Ophthalmic, registered in Europe), and
indomethacin (Indocid, registered in Europe).31 In most of
these formulations, the percentage of CD used for solubiliza-
tion of the drugs was in the range of 10% to 30% wt/
vol.17,18,27,32 The complex forming characteristics of ilomastat
with CD are not known, so we decided to investigate whether
a soluble ilomastat-CD complex could be prepared and then
used as an eye drop to treat the conjunctiva. It was hoped that
complexation of ilomastat with CD, to give ilomastat-CD,
would improve the ocular bioavailability of ilomastat via a
soluble CD complex so that ilomastat could permeate through
the conjunctiva.
MATERIALS AND METHODS
Materials
Ilomastat (388.6 Da) was purchased from Ryss (Union City, CA,
USA). (2-Hydroxypropyl)-b-CD (molecular weight 1380 Da)
was purchased from Sigma Aldrich Corp. (332593-5G; Irvine,
Scotland, UK). Healon GV (1.4% hyaluronic acid [HA] sodium
salt in physiological buffer) was purchased from Moorfields
Pharmaceuticals (London, UK). Acetonitrile (HPLC grade) and
formic acid were purchased from Fisher Scientific UK Ltd.
(Loughborough, UK).
Solubility Studies
Phase solubility studies were conducted to determine the
amount of CD required to solubilize ilomastat. An excess
amount of ilomastat (5 mg) was suspended in water (1 mL) and
stirred for 30 minutes. CD was added slowly to ilomastat
suspension over 10 minutes at concentrations of 0.5%, 1%, 5%,
10%, 15%, and 20% wt/vol. The mixture was left to stir
overnight. The uncomplexed ilomastat was removed by
filtration (0.22 lm polyethersulfone [PES]). The concentration
of ilomastat in the filtrate was determined by HPLC.
Chromatographic Determination
Ilomastat was quantified using HLPC (Agilent 1200 series HPLC
system, Agilent Technologies, London, UK) fitted with a
Synergi RP Phenomenex 4-lm, 15-cm C18 column and
equipped with an autosampler, a degasser, and two SL bin-
pumps. A flow rate of 1 mL/min was used with 0.1%
trifluoroacetic acid in water and acetonitrile as eluents A and
B, respectively, with a linear gradient from 80% A to 70% B in
17 minutes. The detection wavelength was 280 nm.
Preparation of Ilomastat-CD Solution
The percentage of CD that gave the highest ilomastat
solubility was selected from the phase solubility studies.
Ilomastat (4 mg, 0.00001 mol) was suspended in PBS (2 mL)
followed by the slow addition of CD powder (400 mg,
0.00029 mol) (molar ratio of ilomastat/CD is 1:29). The mix-
ture was left to stir overnight. Benzalkonium chloride (BAC)
(0.8 mg) was then added to the mixture, and the mixture was
filtered (0.22 lm PES). Ilomastat concentration in the filtrate
was determined by HPLC (equilibrium concentration was 1.43
6 0.01 mg/mL [n ¼ 4]) and adjusted to 1 mg/mL in PBS [pH
7.4]).
The sodium salt of HA (Healon GV) was used to increase
ilomastat residence time. Healon GV (1.4% wt/vol HA, 0.55
mL) was dissolved in PBS (1.375 mL) to prepare HA 0.4% wt/
vol. HA solution (0.4% wt/vol, 1 mL) was added to 1 mL
ilomastat-CD solution (1 mg/mL) to give clear solution. The
final concentration of ilomastat was 0.5 mg/mL (0.05% wt/vol)
in a clear solution containing CD (10% wt/vol), HA (0.2% wt/
vol), and BAC (0.02% wt/vol) in PBS (pH 7.4).
Permeation Study
The conjunctival permeation studies were conducted using
Franz diffusion cells at 358C. The conjunctivas harvested from
porcine eyes were placed on filter paper and then placed
between donor (volume¼1 mL) and receptor (volume¼2 mL)
chambers within 20 minutes after excision, with an available
area for diffusion of 1 cm2. The receptor chamber was filled
with PBS buffer (pH 7.4, 2 mL). Ilomastat was applied onto the
conjunctiva at a dose of 50 lg (100 lL) as either of ilomastat-
CD HA or ilomastat-CD solution (0.5 mg/mL ilomastat) or 500
lL ilomastat-PBS (100 lg/mL). At time intervals of 10, 30, 60,
90, 120, 180, and 240 minutes, 1 mL of sample was withdrawn
from the receptor chamber and an equal amount of PBS buffer
was added to maintain the original volume. Each experiment
was run in triplicate, and drug concentrations were deter-
mined by HPLC.
Cell Culture
Human Tenon fibroblast cells (HTFs) were maintained in
fibroblast culture medium composed of Dulbecco’s modified
Eagle’s medium (DMEM) supplemented with 10% (vol/vol)
fetal bovine serum (FBS), 2 mM L-glutamine, 100 IU/mL
penicillin, and 100 g/mL streptomycin (all from Gibco Life
Technologies, Paisley, Scotland, UK) at 378C with 5% (vol/vol)
CO2 in air. The medium was changed every 3 to 4 days until
cells reached confluence. The cells were passaged at a ratio of
1:4. Cultures were used between passages 3 and 10 for the gel
contraction experiments.33
Gel Contraction Assay
The free-floating collagen lattice model was used to assess
inhibition of gel contraction by ilomastat.33,34 HTF cells (7 3
104 cells/mL) were seeded in collagen type-1 lattice (150 lL)
in a Matteck dish. The stock solution of ilomastat was
prepared in DMSO. Ilomastat-CD solution (20% CD) in PBS
was filtered and sterilized (0.22 lm). Stock solutions of
ilomastat (DMSO) and ilomastat-CD (PBS) were diluted in
DMEM (FBS, 10% vol/vol) to 0.01, 1, 10, and 100 lM ilomastat.
The drug solutions were added to the lattice (2 mL) at each
individual concentration and incubated at 378C. The gels were
imaged daily from day 0 to day 7, and the percent contraction
was calculated based on the decrease in gel area using ImageJ
software (http://imagej.nih.gov/ij/; provided in the public
domain by the National Institutes of Health, Bethesda, MD,
USA). The shrinkage of the gel was considered as an indicator
of fibrosis activity of the cells.4,33,34 Each formulation was
tested in triplicate.
In Vivo Distribution of Ilomastat
Six female New Zealand White rabbits (2–2.4 kg, 12–14 weeks
old; Harlan Laboratories Ltd., Shardlow, UK) were studied for
ocular drug distribution post eye drop application. These
experiments were performed in accordance with the ARVO
Statement for the Use of Animals in Ophthalmic and Vision
Research. Ilomastat-CD solution (20% CD without HA) (100 lL)
was topically applied to right rabbit eye using a 1-mL insulin
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syringe. After 4 hours, the rabbit eyes were rinsed with water
and removed. Ocular tissues and fluids were isolated immedi-
ately after removal of rabbit eyes and frozen quickly before
being stored at 808C until analyzed.
Extraction of Ilomastat From Ocular Fluids. Ocular
fluid (aqueous humor or vitreous) (200 lL) was spiked with
internal standard marimastat (10 lL, 1 lg/mL). Proteins were
precipitated by adding twice the volume of methanol (400 lL),
vortexed for 5 minutes, then centrifuged at 3396g for 20
minutes. Supernatant was removed and dried by evaporation at
408C under nitrogen. The dried material was then reconstitut-
ed in 100 lL acetonitrile (50% in water) containing 0.1% formic
acid and then analyzed by LC-MS.
Extraction of Ilomastat From Ocular Tissues. Ocular
tissues (sclera, conjunctiva, and cornea) were dissected, then
frozen quickly in dry ice and stored at 808C. Tissues were
lyophilized, and the weight of the dry tissue was recorded. PBS
(pH 7.4) was added to ocular tissues (800 lL) and incubated
for 1 hour at 558C. Proteinase K (1 mg/mL in PBS) equal
volume was added to tissues and then incubated at 558C for 4
hours with shaking (1.77g). Tissue homogenates were vortex-
ed for 5 minutes. Proteins were precipitated by adding double
the volume of methanol followed by vortexing for 5 minutes.
Supernatant was then removed. An equal volume of diethyl
ether was added to the supernatant to precipitate fatty acids.
Solutions were mixed and centrifuged at 3396g for 20 minutes.
Supernatants were removed and concentrated under vacuum
to 1 mL. Distilled water (2 mL) was then added to the
concentrated solution. Liquid-liquid extraction was then
conducted by adding 9 mL ethyl acetate to the aqueous
solution followed by vigorous mixing. The extraction solutions
were left to mix for 48 hours. Then the ethyl acetate phase was
carefully collected using a glass pipette and dried by
evaporation at 408C under nitrogen. The dried material was
then reconstituted in 100 lL acetonitrile (50% in water)
containing 0.1% formic acid, then analyzed by liquid chroma-
tography-mass spectroscopy (LC-MS).
LC-MS Analysis
An Agilent Zorbax Eclipse Plus C18 (3.5 lm, 50 3 2.1 mm;
Agilent Technologies, London, UK) column was used with a
mobile phase consisting of solvent A (0.1% formic acid in
water) and solvent B (0.1% formic acid in acetonitrile), and
gradient elution was used (Supplementary Table S1). Flow
rate was 200 lL/min, and run time was 7 minutes. Ilomastat
and marimastat eluted at 3.10 and 2.96 minutes, respectively.
Triple quadrupole LC-MS (TSQ Quantum Access; Thermo
Scientific, London, UK) was used. SRM scan for both parent
compound and ion products mass (mass-to-charge ratio, m/z)
was conducted and recorded over masses of 50 to 450. In the
first scan, the parent ilomastat and marimastat masses [MþH]
were 389.36 and 332.31, respectively. In the second scan,
ionization of the parent compounds was conducted. The
most abundant fragments were selected for ilomastat m/z of
356.06 and 227.02 and for marimastat m/z of 301.03 and
273.03. Collision energy used was 12 and 10 for ilomastat and
marimastat, respectively. Quantification of ilomastat in ocular
tissues and fluids was accomplished by constructing a
calibration curve of area under the curve ratio (drug/internal
standard) versus concentration. The area under the curve was
calculated using ilomastat m/z 356 and marimastat m/z 301
for ocular fluids. For ocular tissues the peak used to quantify
ilomastat was m/z 227. The data were expressed in average
nanomolars 6 standard error of the mean for ocular fluids and
average picogram per milligram of tissue 6 standard error of
the mean.
RESULTS
Formation and Solubility of Ilomastat-CD
The solubility of ilomastat in water and PBS was proportional
to the amount of CD that was added (Fig. 1). The highest
solubility of ilomastat in water was achieved by using CD 20%
wt/vol. The solubility after gentle stirring of ilomastat/CD
mixture was 630.1 lg/mL after 1 day and increased to 1029.1
lg/mL after 2 days. There was no change in the ilomastat HPLC
profile. Poly(vinylpyrrolidone) (PVP; 0.25%–1.0% wt/vol),
known to improve the solubility of some CD complexes
through the formation of a ternary complex with drug-CD
complex,35,36 was examined in an effort to further improve the
solubility of the ilomastat-CD complex. However, the addition
of PVP to ilomastat-CD (20% wt/vol) only slightly increased the
solubility of ilomastat in water (1137.6 lg/mL) after being
stirred for 2 days (Supplementary Fig. S1). Alexanian et al.36
reported comparable findings where PVP did not enhance the
solubility of nimesulide-CD complex. PVP solubility enhance-
ment appears to depend considerably on the drug.36,37
Our aim was to improve the solubility of ilomastat at pH 7.4,
which is the optimum physiological pH for topical ophthalmic
administration. A mild and relevant solution such as PBS at pH
7.4 can be used to administer ilomastat to treat irritated,
injured eyes to aid the healing process. Our strategy is
supported by other studies that describe the use of CD to
improve drug solubility at a fixed pH that would be used in the
final formulation.18,38,39 Better ilomastat solubility was
achieved as the CD complex in PBS (1439.93 6 5.96 lg/mL)
using CD at a concentration of 20% wt/vol after 1 day of gentle
stirring of the ilomastat/CD mixture (Fig. 1). From these
solubility studies, PBS (pH 7.4) was found to be the best
solvent for preparation of topical ilomastat-CD complex
solution using 20% wt/vol CD.
Permeation Studies
The permeation of ilomastat through pig conjunctiva ex vivo
was examined at an ilomastat dose of 50 lg (100 lL ilomastat-
CD, 500 lg/mL). Ilomastat in PBS was included as control at a
concentration of 100 lg/mL (500 lL). The permeation of
ilomastat through pig conjunctiva increased with incubation
time (Fig. 2). HA was also evaluated as an excipient at a
concentration similar to that used in an existing commercial
artificial tear product40 in an effort to develop ilomastat-CD
formulation with more optimal properties on the ocular
FIGURE 1. Solubility of ilomastat-CD (CD is 1%–20% wt/vol) in PBS (pH
7.4) ( ) and water at room temperature ( ) after stirring
for 1 day (n ¼ 3).
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surface. Several studies report that HA can be used to increase
the residence time of a drug on the surface of the eye,41,42
which could be beneficial to increase the concentration of
ilomastat in the subconjunctival space. Although the perme-
ation profiles are similar, the ilomastat-CD complex without HA
displayed higher permeation than ilomastat-CD containing
0.2% HA and pure ilomastat (Fig. 2). Complexation of ilomastat
with CD helped to increase the permeation of ilomastat
through the conjunctiva. In contrast, the presence of HA in the
ilomastat-CD solution eliminated the enhanced penetration
effect of CD. The reduced permeation of ilomastat-CD
containing 0.2% HA may be due to the need for ilomastat to
diffuse through the viscous HA solution, so we decided to use
ilomastat-CD solutions only as eye drop without addition of HA.
In Vitro Efficacy of Ilomastat-CD
An in vitro assay utilizing HTFs seeded on collagen and then
measuring collagen contraction is often used to evaluate the
potential antifibrotic activity of candidate drugs in vitro.4
Exposure of both ilomastat and ilomastat-CD significantly
inhibited collagen gel contraction over a 7-day incubation
period (Fig. 3). Ilomastat-CD displayed inhibition of gel
contraction similar to ilomastat at all concentrations that were
examined. At day 7, at an ilomastat concentration range of 1 to
100 lM, ilomastat-CD displayed 18.42% 6 4.09% to 23.72% 6
1.22% gel contraction, which is similar to pure ilomastat
(19.09% 6 0.55% to 25.82% 6 1.04% gel contraction). Both
pure ilomastat and ilomastat-CD at a concentration of 0.01 lM
were less effective at inhibiting collagen gel contraction
(51.79% 6 2.05% and 46.81% 6 2.12% gel contraction,
respectively).
In Vivo Distribution of Ilomastat
The ocular distribution of ilomastat in rabbit eyes was
evaluated 4 hours after administration of ilomastat-CD solution
(20% CD without HA) (100 lL, 1 mg/mL). The level of
ilomastat in the aqueous humor was 37.156 3 1.42 nM (n¼3).
There was a negligible amount of ilomastat in the vitreous
(0.07 6 0.05 nM) (n ¼ 4). The level of ilomastat in the sclera
was 2-fold higher than in conjunctiva and cornea (Table).
These levels are within the known therapeutic concentration
range of ilomastat that would be expected by subconjunctival
injection to treat fibrosis after glaucoma surgery.6,7 Both the
conjunctiva and cornea displayed similar levels of ilomastat
(Table). This result is promising as topical administration of
ilomastat-CD could also be considered to treat corneal injury.
DISCUSSION
These results show that it is possible to formulate ilomastat by
complexation with CD. Ilomastat has poor water solubility, and
FIGURE 2. Permeation profile of ilomastat-CD (50 lg ilomastat) in pig’s
conjunctiva in vitro at 358C. (A) Ilomastat cumulative permeation (lg)
per surface area of pig’s conjunctiva (cm2). (B) Percentage of ilomastat
initial dose that permeated through pig’s conjunctiva. Ilomastat-CD
containing 0.2% HA wt/vol ( ), ilomastat-CD ( ) and pure
ilomastat in PBS solutions ( ). Data are average 6 standard
deviation (n¼ 3).
FIGURE 3. Effect of ilomastat on ocular fibroblast-mediated collagen contraction at different concentrations (0.01 , 1 , 10 , and 100
lM). (A) Pure ilomastat solubilized in DMSO and (B) ilomastat-CD complex. DMSO (% vol/vol in DMEM) ( ) and DMEM blank ( )
were included as control. Data are average 6 standard deviation (n ¼ 3).
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the solubility of ilomastat was improved by complexation with
CD. Inflammation and fibrosis are the main cause of the failure
of glaucoma filtration surgery (GFS).43 Ilomastat is a wide-
spectrum MMPi that has shown improved GFS outcome in
rabbits by repeated subconjunctival injection.6,7
CDs are widely used to improve the aqueous solubility of
poorly soluble drugs.16 2-Hydroxypropyl-b-cyclodextrin was
selected to prepare a soluble form of ilomastat because this CD
(1) is in eye drops for human use,44,45 (2) is nontoxic for
topical ophthalmic use,16,44,46 and (3) has high water solubility
(450 mg/mL).47 Several methods were investigated to prepare
the ilomastat-CD complex, including (1) mixing ilomastat
dissolved in aqueous tert-butanol (40% vol/vol) with an
aqueous solution of CD, then freeze drying (the lyophilised
powder was not soluble in water); (2) mixing a suspension of
ilomastat with aqueous CD (the drug remained insoluble); and
(3) using solid addition method (CD powder was added slowly
to an aqueous suspension of ilomastat). This last method
successfully solubilized ilomastat and maintained ilomastat
solubility after freeze drying. Complexation of ilomastat with
CD did not affect the in vitro activity of ilomastat. Several
studies reported that complexation of drugs to CD did not
impair their biological activities in the eye,17,27,28 probably due
to a reversible equilibrium between free drug and drug-CD.16
The presence of CD might facilitate permeation of
ilomastat through ocular tissues. CD binds to biological
membranes and increases the permeability of the complexed
drug.48,49 This was confirmed by (1) increased permeation of
ilomastat through pig conjunctiva in vitro compared to pure
ilomastat and (2) the presence of ilomastat in ocular tissues
and fluids after topical administration of ilomastat-CD
solutions. Cyclodextrin has been reported to increase
permeability of drugs such as sirolimus,50 natamycin,19
tranilast,51 hesperidin,52 ketoconazole,53 pilocarpine,25,54
and thalidomide26 through ocular tissues after topical
application. This is important, as much of the therapeutic
effect for ocular drops depends on penetration into ocular
tissues.
The biodistribution studies revealed that the concentration
of ilomastat was within the therapeutic range (10–100 nM)4,6,7
in both ocular tissues (sclera and conjunctiva) and fluids
(aqueous humor). These results suggest that the ilomastat-CD
complex has the potential to be used as a topical modulator of
ocular wound healing.
CONCLUSIONS
Complexation of ilomastat with CD improved its solubility and
permeability through ocular tissues with retention of its in
vitro activity. In vivo biodistribution studies displayed the
presence of ilomastat at a therapeutic concentration in sclera,
conjunctiva, and aqueous humor. These promising results
reveal that topical application of ilomastat might be successful
to inhibit scarring following glaucoma surgery. More work
needs to be conducted to establish the in vivo efficacy of the
ilomastat-CD eyedrop.
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